Form D · Biotechnology
Tarveda Therapeutics, Inc.
Watertown, MA · CIK 0001528747
Offering snapshot reported Sep 27, 2021 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 15, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 27, 2021 | Initial | $5,999,999 | No comparison | 1 | SEC filing |
| Dec 28, 2020 | Initial | $14,999,994 | No comparison | 8 | SEC filing |
| Dec 26, 2019 | Initial | $13,634,188 | No comparison | 13 | SEC filing |
| Feb 9, 2017 | Initial | $30,000,001 | No comparison | 7 | SEC filing |
| Feb 9, 2017 | Amendment | $38,000,000 | $12,480,822vs Jan 29, 2016 | 8 | SEC filing |
| Jan 29, 2016 | Initial | $25,519,178 | No comparison | 8 | SEC filing |
| Mar 12, 2014 | Initial | $999,999 | No comparison | 1 | SEC filing |
| Dec 24, 2013 | Amendment | $21,001,164 | $4,999,996vs Dec 20, 2012 | 9 | SEC filing |
| Dec 20, 2012 | Initial | $16,001,168 | No comparison | 8 | SEC filing |
| Sep 2, 2011 | Initial | $2,800,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-414683
Source: Form D, filed Sep 27, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leila Alland | Executive |
| Shadi Aryanpour | Executive |
| Dennis Ausiello | Director |
| James Barrett | Director |
| David Berry | Director |
| Omid Farokhzad | Director |
| Andrew J. Fromkin | Director, Executive |
| Peter Barton Hutt | Director |
| Mark Iwicki | Director, Executive |
| Edwin M. Kania | Director |
| Nilesh Kumar | Director |
| Robert Langer | Director |
| Robert S. Langer, Jr. | Director |
| Guido Magni | Director |
| Michael Metzger | Director |
| Jeffrey Quillen | Executive |
| Brian Roberts | Director, Executive |
| Aymeric Sallin | Director |
| Frank Torti | Director |
| Richard Wooster | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
134 Coolidge Avenue
Watertown, MA, 02472
Watertown, MA, 02472